Alex Fryé
About Alex Fryé
Alex Fryé is a Senior Associate Scientist specializing in Engineered T Cell Biology in Immuno-Oncology & Cell Therapy at Bristol Myers Squibb in Seattle, Washington.
Title
Alex Fryé holds the position of Senior Associate Scientist in Engineered T Cell Biology within Immuno-Oncology and Cell Therapy at Bristol Myers Squibb. The role involves specializing in the intersection of immunotherapy and synthetic biology.
Current Position at Bristol Myers Squibb
Alex Fryé is currently employed at Bristol Myers Squibb in Seattle, Washington, United States. As a Senior Associate Scientist, he focuses on Engineered T Cell Biology in Immuno-Oncology and Cell Therapy, contributing towards innovative treatments and the advancement of cancer therapies.
Previous Experience
Before joining Bristol Myers Squibb, Alex Fryé worked in several roles within the biomedical and research sectors. He served as a Research Associate II at the Earle A. Chiles Research Institute's Basic Immunology Lab in Portland, Oregon, from 2018 to 2020. He was also a Visiting Scientist at the Benaroya Research Institute at Virginia Mason, specifically within the Buckner Lab, in 2018. Additionally, he has experience as a Technician and Administrative Coordinator at TechForm Advanced Casting Technology from 2015 to 2016, and as a Research Assistant at the Food and Agribusiness Institute at Santa Clara University from 2013 to 2014.
Education and Expertise
Alex Fryé completed his Master of Science in Biomedical Sciences at the University of Groningen, graduating Cum Laude in 2018. His education also includes a Bachelor of Science in Public Health with minors in Biology and Sociology from Santa Clara University, where he graduated Cum Laude in 2014. Throughout his academic journey, he has focused on various aspects of biomedical sciences, including anatomy, medical neuroscience, and data science.
Published Research
Alex Fryé has made his mark in the scientific community through published research. His work on the gut-brain-axis has contributed to the broader understanding of its roles in immunotherapy. Furthermore, he authored a research paper on synthetic biology published in Nature Communications, showcasing his expertise and active participation in cutting-edge scientific discovery.